CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 20, 2018--
Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia-inducible factor (HIF), today
announced that it will participate in the following investor conferences:
The 30th Annual Piper Jaffray Healthcare Conference onWednesday, November 28, 2018, at 12:30 p.m. Eastern Time at the Lotte
New York Palace Hotel. Akebia will participate in a fireside chat
- The Global Mizuho Investor Conference on Monday, December 3, 2018, at
the Lotte New York Palace Hotel.
A replay of the webcast from the Piper Jaffray Healthcare Conference
will be available on the company’s website at www.akebia.com
the day following the conference. To access, please log onto the Akebia
website at least 15 minutes prior to the webcast to ensure adequate time
for any software downloads that may be required.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through hypoxia-inducible factor
biology. For more information, please visit our website at www.akebia.com,
which does not form a part of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005661/en/
Source: Akebia Therapeutics, Inc.
Director, Corporate Communications